Clinically, EGFR-TKIs targeted therapies (gefitinib, erlotinib, icotinib) result in very favorable outcomes with PFS of 10–13 months for patients with advanced NSCLC harboring somatic EGFR mutations (Exon 19-del, Exon 21 L858R) (Sequist et al. 2008). Here, EGFR is linked to non-small cell lung carcinoma.